Monograph

L04AC03 - Anakinra

Propably not porphyrinogenic

Important Information

Patients on immunosuppressive therapy have an increased risk of infections. Since infections have a potential to trigger acute porphyric attacks vigilance is motivated regarding signs or symptoms of infection and/or possible symptoms of a porphyric attack.

Side effects

Infections are common in patients using immunosuppressants and since infections might trigger an acute porphyric attack, vigilance regarding signs and symptoms of an infection and/ or a porphyric attack is recommended.

Rationale

Antibody preparation with no CYP metabolism. Based on the pharmacokinetics, Anakinra is not expected to have any porphyrinogenic effects.

Chemical description

Human interleukin 1 receptor antagonist produced in Escherichia coli cells by recombinant DNA technology.

Therapeutic characteristics

Anakinra is used in the treatment of rheumatoid arthritis as monotherapy or in combination with methotrexate in patients with an inadequate response to methotrexate alone. It is administered as a subcutaneous injection.

Metabolism and pharmacokinetics

Anakinra is not metabolised by the liver via phase 1 mechanisms and is not known to inhibit cytochrome P450 enzymes. The metabolism of anakinra is expected to be similar as for endogenous antibodies, which are metabolised to peptides and amino acids in various body tissues and in plasma by circulating phagocytic cells or by their target antigen-containing cells.

References

#	Citation details	PMID
*	Drug reference publications
1.	Sweetman SC, editor. Martindale: The complete drug reference. Anakinra. Pharmaceutical Press 2009.
*	Government bodies
2.	European Public Assessment Report, Kineret (Scientific discussion).European Medicines Agency (EMEA). Accessible from: emea.europa.eu
*	Summary of Product Characteristics
3.	The electronic Medicines Compendium (emc). Summary of Product Characteristics (SPC). Kineret. (Last edition: November 2013).

Citation details

PMID

Drug reference publications

Sweetman SC, editor. Martindale: The complete drug reference. Anakinra. Pharmaceutical Press 2009.

Government bodies

European Public Assessment Report, Kineret (Scientific discussion).European Medicines Agency (EMEA). Accessible from: emea.europa.eu

Summary of Product Characteristics

The electronic Medicines Compendium (emc). Summary of Product Characteristics (SPC). Kineret. (Last edition: November 2013).

Similar drugs

Explore alternative drugs in similar therapeutic classes L04A / L04AC or go back.

Tradenames and packages

From some sources, we get a list of packages (United Kingdom, Ireland, Estonia). Other sources contain more or less "clean" versions of the trade name (Denmark, Finland, Iceland, Lithuania, Norway). What you see here is the raw data we get from each country, so there will appear to be duplicates. The bold names are the searchable terms. The gray names that follow are all mapped to the bolded term.

Note: The cleaning is done automatically by a proprietary algorithm, and it may produce errors. We strive to improve it continuously.

Netherlands